# Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

> **NCT00694850** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 22 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521).

## Key facts

- **NCT ID:** NCT00694850
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-02
- **Primary completion:** 2025-07-03
- **Final completion:** 2025-07-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694850, "Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00694850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*